CoLucid Pharmaceuticals, Inc.
CLCD
CLCD was delisted on the 28th of February, 2017.
0 hedge funds and large institutions have $0 invested in CoLucid Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $55K → $0 (-$55K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FPF
FNY Partners Fund
New York
|
-$55K |
CLCD Hedge Fund Activity: Q2 2017 in Review
0 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q2 2017, worth a combined $0 — down 100% from $55K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CLCD and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was FNY Partners Fund, exiting entirely with an estimated $55K sold.
- 0 institutional investors held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q2 2017, down from 1 in Q1 2017.
- Funds reported $0 of CoLucid Pharmaceuticals, Inc. stock for Q2 2017, down 100% quarter-over-quarter.
- 0 funds opened new CoLucid Pharmaceuticals, Inc. positions in Q2 2017 and 1 closed out, a net change of -1 holder.
- The largest CoLucid Pharmaceuticals, Inc. seller in Q2 2017 was FNY Partners Fund, an estimated $55K sold.
Based on aggregated 13F filings for Q2 2017.